Q32 Bio Inc

Research Q32 Bio Inc (QTTB) on Bullrun: valuation model: 105.2% undervalued, market cap USD 239.76M, P/E 5.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerQTTB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal105.2% undervalued
• Market capUSD 239.76M
• P/E5.3
• Financial periodFY2025
• RevenueUSD 53.74M
• Net incomeUSD 29.80M
• Free cash flow-USD 33.54M

Valuation Snapshot

Bullrun's latest valuation model marks Q32 Bio Inc as 105.2% undervalued; latest market cap is USD 239.76M; P/E is 5.3.

About Q32 Bio Inc

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.

Frequently asked questions

Is Q32 Bio Inc overvalued or undervalued?

Bullrun's valuation model currently marks Q32 Bio Inc as 105.2% undervalued.

What is Q32 Bio Inc's market cap?

Q32 Bio Inc's market capitalization is USD 239.76M.

What is Q32 Bio Inc's P/E ratio?

Q32 Bio Inc's price-to-earnings (P/E) ratio is 5.3.

What does Q32 Bio Inc do?

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.